Prevalence and factors associated with urinary schistosomiasis in women attending cervical cancer screening in Sithobela, Eswatini: A facility-based cross-sectional study
Helminthologia · 01.12.2025 · 62 (4) · 296-303
DOI: 10.2478/helm-2025-0034 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Helminthologia, online erschienen am 31.12.2025. Verfasst von M N Mathobela und 4 weiteren Autor:innen. Beteiligte Einrichtung: Master of Public Health Program, Texila American University, Lusaka, Zambia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Urinary schistosomiasis remains endemic in sub-Saharan Africa, yet data on women of reproductive age are limited. This study aimed to determine the prevalence of Schistosoma haematobium infection and to identify associated sociodemographic and exposure-related factors - including employment status - among women attending cervical cancer screening in Eswatini. A facility-based cross-sectional study was conducted at Sithobela Health Centre (Lowveld region) between September and October 2023. Using convenience sampling, 360 women aged 20 – 49 years attending routine screening were enrolled. Sociodemographic characteristics (including education and employment/occupation) and water-related exposures were collected using a semi-structured questionnaire. A single mid-morning 10-mL urine sample was examined by sedimentation microscopy, and infection was defined as ≥1 S. haematobium egg per 10 mL of urine. Data were analyzed using descriptive statistics and multivariable logistic regression. The prevalence of urinary schistosomiasis was 10.83% (39/360). Women older than the median age (26 years) had higher odds of infection (AOR 2.29, 95% CI 1.04 – 5.05; p = 0.04), while secondary education or higher was associated with lower odds (AOR 0.38, 95% CI 0.16 – 0.89; p = 0.03). Employment status (employed vs unemployed) was not associated with infection (AOR 0.89, 95% CI 0.39 – 2.02; p = 0.79). Use of open or protected wells was associated with lower odds compared with tap water (AOR 0.14, 95% CI 0.05 – 0.35; p < 0.01). Urinary schistosomiasis persists among women attending cervical cancer screening, supporting inclusion of women of reproductive age in control strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Master of Public Health Program, Texila American University, Lusaka, Zambia.
- Malaria & Neglected Tropical Diseases Program, Ministry of Health, Mbabane, Eswatini.
- Department of Molecular Parasitology and Tropical Diseases, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Research Center of International Tropical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Behavioral Research and Innovations Unit, Educational Youth Empowerment, Manzini, Eswatini.
- Strategic Information Department, Ministry of Health, Mbabane, Eswatini.
Zitieren
APA
Mathobela, M. N., Chuang, T. W., Chen, P. C., Motsa, M. P. S., & Fan, C. K. (2025). Prevalence and factors associated with urinary schistosomiasis in women attending cervical cancer screening in Sithobela, Eswatini: A facility-based cross-sectional study. Helminthologia, 62(4), 296-303. https://doi.org/10.2478/helm-2025-0034
Vancouver
Mathobela MN, Chuang TW, Chen PC, Motsa MPS, Fan CK. Prevalence and factors associated with urinary schistosomiasis in women attending cervical cancer screening in Sithobela, Eswatini: A facility-based cross-sectional study. Helminthologia. 2025;62(4):296-303. doi:10.2478/helm-2025-0034
BibTeX
@article{Mathobela2025,
author = {Mathobela, M N and Chuang, T W and Chen, P C and Motsa, M P S and Fan, C K},
title = {Prevalence and factors associated with urinary schistosomiasis in women attending cervical cancer screening in Sithobela, Eswatini: A facility-based cross-sectional study},
journal = {Helminthologia},
year = {2025},
volume = {62},
number = {4},
pages = {296--303},
doi = {10.2478/helm-2025-0034}
}
EUVIMED